SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-24-001172
Filing Date
2024-02-14
Accepted
2024-02-14 17:10:29
Documents
70
Period of Report
2023-12-31

Document Format Files

Seq Description Document Type Size
1 10-Q otlk-20231231x10q.htm   iXBRL 10-Q 1253276
2 EX-31.1 otlk-20231231xex31d1.htm EX-31.1 9607
3 EX-31.2 otlk-20231231xex31d2.htm EX-31.2 12103
4 EX-32.1 otlk-20231231xex32d1.htm EX-32.1 9512
  Complete submission text file 0001558370-24-001172.txt   6625373

Data Files

Seq Description Document Type Size
5 EX-101.SCH otlk-20231231.xsd EX-101.SCH 45991
6 EX-101.CAL otlk-20231231_cal.xml EX-101.CAL 35398
7 EX-101.DEF otlk-20231231_def.xml EX-101.DEF 239272
8 EX-101.LAB otlk-20231231_lab.xml EX-101.LAB 380152
9 EX-101.PRE otlk-20231231_pre.xml EX-101.PRE 350272
72 EXTRACTED XBRL INSTANCE DOCUMENT otlk-20231231x10q_htm.xml XML 1169448
Mailing Address 485 ROUTE 1 SOUTH BUILDING F, SUITE 320 ISELIN NJ 08830
Business Address 485 ROUTE 1 SOUTH BUILDING F, SUITE 320 ISELIN NJ 08830 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

IRS No.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 10-Q | Act: 34 | File No.: 001-37759 | Film No.: 24640432
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)